EXACT Sciences Corporation (OQ:EXAS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 441 Charmany Dr
MADISON WI 53719-1234
Tel: N/A
Website: www.exactsciences.com
IR: See website
Key People
Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Jeffrey Thomas Elliott
Chief Financial Officer
Mark Stenhouse
President, Cologuard
D. Scott Coward
Senior Vice President, Chief Administrative Officer, General Counsel, Secretary
Graham Peter Lidgard
Senior Vice President, Chief Scientific Officer
Ana Hooker
Senior Vice President, Operations
Scott Johnson
Senior Vice President, Research & Development
Business Overview
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Financial Overview
For the nine months ended 30 September 2019, EXACT Sciences Corporation revenues increased 86% to $580.7M. Net loss increased 34% to $161.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 53% to $134.5M (expense), Personnel Expenses increase of 96% to $87.6M (expense), Selling/General/Admin.
Employees: 1,977 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $11,323M as of Sep 30, 2019
Annual revenue (TTM): $723.70M as of Sep 30, 2019
EBITDA (TTM): -$155.93M as of Sep 30, 2019
Net annual income (TTM): -$215.91M as of Sep 30, 2019
Free cash flow (TTM): -$271.61M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 147,232,089 as of Nov 8, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization